Clinical trials
Completed Scleroderma, Diffuse trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 5 |
| 2002 | 3 |
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 74 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Michigan | 11 |
| Johns Hopkins University | 5 |
| Boston University | 3 |
| MediQuest Therapeutics | 3 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 3 |
| Bristol-Myers Squibb | 2 |
| Dinesh Khanna, MD, MS | 2 |
| Duke University | 2 |
| MedImmune LLC | 2 |
| Medical University of South Carolina | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Diffuse | 74 |
| Scleroderma, Systemic | 33 |
| Raynaud Disease | 11 |
| Autoimmune Diseases | 6 |
| Sjogren's Syndrome | 5 |
| Arthritis, Rheumatoid | 4 |
| Hypertension, Pulmonary | 4 |
| Lung Diseases, Interstitial | 4 |
| Lupus Erythematosus, Systemic | 4 |
| Scleroderma, Localized | 4 |
Trials
Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.